A clinical study will begin Monday at the university hospital of Mechelen on the drug Sarconeos, the effects of which could be positive for patients in respiratory failure, one of the symptoms of the Covid-19. In the case of a positive result, the drug will not be immediately available on the market.
Developed by the French biotech Biophytis, the drug will be tested on a fifty patients of the university hospital of Malines for the treatment of pneumonia to a serious stage, caused by the Covid-19.
